Willingness to participate in entheogen use research in naturalistic settings

Kirk, Riley D.; Uhley, Olivia M.; Lehfeldt, Paloma; Shields, C. Miyabe; Garretson, Marné; Collins, Alanna; Wahbeh, Helané; Dahmer, Stephen

doi:10.1556/2054.2022.00238

Cited by 1 publication

(1 citation statement)

References 18 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adding to this, local regulation due to the pandemic may have produced differences in access to drugs. Since context can influence psychedelic experiences in a naturalistic setting ( 61 ), it cannot be ruled out that these factors contributed to the outcomes we report. More specifically, it is not excluded that psychedelics use in the UK (where strict lockdown and infection control guidelines were employed) during the COVID-19 pandemic could have led to the amplification of general distress, which would have in turn influenced the outcome of psychedelic experiences.…”

Section: Discussionmentioning

confidence: 98%

Associations between the use of psychedelics and other recreational drugs with mental health and resilience during the COVID-19 pandemic

et al. 2023

View full text Add to dashboard Cite

The large-scale disruption to peoples’ daily lives during the COVID-19 pandemic provides a context for examining whether use of substances such as psychedelics in a naturalistic (outside of a controlled environment) setting, is associated with better mental wellbeing and resilience relative to those who use other drugs, or who do not use drugs at all. We interrogate data from the Great British Intelligence Test and identify that 7.8% out of N = 30,598 unique respondents used recreational drugs inclusive of psychedelics, cannabis, cocaine, and MDMA during the COVID-19 pandemic. Recruitment materials did not mention drug use would be surveyed, thereby enabling us to model the relationship with mood and resilience in people who had not specifically self-selected themselves for a ‘drug’ study. We report that people form clusters, characterized by different real-world patterns of drug use, and the majority of psychedelics users also use cannabis. However, a subset of cannabis users do not use psychedelics, enabling a subtractive comparison. Those who primarily used psychedelics and cannabis during the COVID-19 pandemic had worse mood self-assessment and resilience scores compared to those who never used drugs or primarily used cannabis. This pattern was also evident for other recreational drug use clusters, except for those who primarily used MDMA and cannabis, who had better mood but were of too low incidence to have confidence in this estimate. These findings cast light on the significant differences in mental wellbeing between users of different drugs and the non-user population during a global-crisis and call for future research to explore the pharmacological, contextual and cultural variables associated with these differences, their generalisability and causal links with greater precision.

show abstract

Section: Discussionmentioning

confidence: 98%